Elliot Management is once again placing pressure on Alexion Pharmaceuticals to pursue a sale of the company after first advocating for the sale in late 2019.
“The best approach for the Company and its stakeholders is the immediate exploration of a sale, which, as explained below, would create significant upside for shareholders while creating a more stable footing for all those with a vested interest in Alexion’s future – including its patients.”
Elliott Advisors Letter to Alexion Board of Directors
The catalyst for the public letter was the announcement by Alexion last week that they would be acquiring Portola Pharmaceuticals, a deal which was not received well by investors.